| 000 | 01859 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514055229.0 | ||
| 264 | 0 | _c20040426 | |
| 008 | 200404s 0 0 eng d | ||
| 022 | _a0952-3278 | ||
| 024 | 7 |
_a10.1016/s0952-3278(02)00231-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHarding, Pamela | |
| 245 | 0 | 0 |
_aCOX-2 inhibition potentiates the antiproteinuric effect of enalapril in uninephrectomized SHR. _h[electronic resource] |
| 260 |
_bProstaglandins, leukotrienes, and essential fatty acids _cJan 2003 |
||
| 300 |
_a17-25 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xpharmacology |
| 650 | 0 | 4 | _aBlood Pressure |
| 650 | 0 | 4 | _aBody Weight |
| 650 | 0 | 4 |
_aCollagen Type II _xmetabolism |
| 650 | 0 | 4 | _aCyclooxygenase 2 |
| 650 | 0 | 4 | _aCyclooxygenase 2 Inhibitors |
| 650 | 0 | 4 |
_aCyclooxygenase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aEnalapril _xpharmacology |
| 650 | 0 | 4 |
_aHypertrophy _xpathology |
| 650 | 0 | 4 |
_aIsoenzymes _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aKidney Diseases _xenzymology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNephrectomy |
| 650 | 0 | 4 |
_aNitrobenzenes _xpharmacology |
| 650 | 0 | 4 | _aOrgan Size |
| 650 | 0 | 4 |
_aProstaglandin-Endoperoxide Synthases _xphysiology |
| 650 | 0 | 4 |
_aProstaglandins _xurine |
| 650 | 0 | 4 |
_aProteinuria _xenzymology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Inbred SHR |
| 650 | 0 | 4 | _aRats, Inbred WKY |
| 650 | 0 | 4 |
_aSulfonamides _xpharmacology |
| 700 | 1 | _aGlass, William F | |
| 700 | 1 | _aScherer, Steven D | |
| 773 | 0 |
_tProstaglandins, leukotrienes, and essential fatty acids _gvol. 68 _gno. 1 _gp. 17-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0952-3278(02)00231-4 _zAvailable from publisher's website |
| 999 |
_c12339953 _d12339953 |
||